CN1309735C - 可溶性ctla4突变体分子及其应用 - Google Patents

可溶性ctla4突变体分子及其应用 Download PDF

Info

Publication number
CN1309735C
CN1309735C CNB018101453A CN01810145A CN1309735C CN 1309735 C CN1309735 C CN 1309735C CN B018101453 A CNB018101453 A CN B018101453A CN 01810145 A CN01810145 A CN 01810145A CN 1309735 C CN1309735 C CN 1309735C
Authority
CN
China
Prior art keywords
ctla4
mutant molecule
molecule
cell
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018101453A
Other languages
English (en)
Chinese (zh)
Other versions
CN1441810A (zh
Inventor
R·J·皮奇
J·R·奈穆拉
P·S·林斯利
J·巴约拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN1441810A publication Critical patent/CN1441810A/zh
Application granted granted Critical
Publication of CN1309735C publication Critical patent/CN1309735C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018101453A 2000-05-26 2001-05-23 可溶性ctla4突变体分子及其应用 Expired - Lifetime CN1309735C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US09/579,927 2000-05-26
US21406500P 2000-06-26 2000-06-26
US60/214,065 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007100840790A Division CN101255192A (zh) 2000-05-26 2001-05-23 可溶性ctla4突变体分子及其应用

Publications (2)

Publication Number Publication Date
CN1441810A CN1441810A (zh) 2003-09-10
CN1309735C true CN1309735C (zh) 2007-04-11

Family

ID=26908652

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018101453A Expired - Lifetime CN1309735C (zh) 2000-05-26 2001-05-23 可溶性ctla4突变体分子及其应用
CNA2007100840790A Pending CN101255192A (zh) 2000-05-26 2001-05-23 可溶性ctla4突变体分子及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007100840790A Pending CN101255192A (zh) 2000-05-26 2001-05-23 可溶性ctla4突变体分子及其应用

Country Status (41)

Country Link
EP (3) EP1248802B9 (enExample)
JP (1) JP4328525B2 (enExample)
KR (2) KR100895134B1 (enExample)
CN (2) CN1309735C (enExample)
AR (1) AR031699A1 (enExample)
AT (1) ATE271066T1 (enExample)
AU (2) AU6346601A (enExample)
BE (1) BE2011C041I2 (enExample)
BR (1) BRPI0111191B8 (enExample)
CA (1) CA2409748C (enExample)
CY (2) CY2011019I1 (enExample)
CZ (1) CZ304451B6 (enExample)
DE (2) DE60104282T2 (enExample)
DK (1) DK1248802T3 (enExample)
EC (1) ECSP024365A (enExample)
EE (2) EE05458B1 (enExample)
EG (1) EG24459A (enExample)
ES (2) ES2225549T3 (enExample)
FR (1) FR11C0053I2 (enExample)
GE (1) GEP20053658B (enExample)
HK (1) HK1048126B (enExample)
HU (2) HU228137B1 (enExample)
IL (1) IL152315A (enExample)
LT (1) LT5133B (enExample)
LU (1) LU91902I2 (enExample)
LV (1) LV12994B (enExample)
MX (1) MXPA02011534A (enExample)
MY (1) MY136113A (enExample)
NO (2) NO330797B1 (enExample)
PE (1) PE20011338A1 (enExample)
PL (1) PL206267B1 (enExample)
PT (1) PT1248802E (enExample)
RU (1) RU2283847C2 (enExample)
SI (1) SI1248802T1 (enExample)
SK (1) SK288131B6 (enExample)
TR (1) TR200402703T4 (enExample)
TW (2) TWI314933B (enExample)
UA (1) UA87432C2 (enExample)
UY (1) UY26723A1 (enExample)
WO (1) WO2001092337A2 (enExample)
ZA (1) ZA200208944B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432474A (zh) * 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
HU226847B1 (en) * 2000-07-03 2009-12-28 Bristol Myers Squibb Co Use of soluble ctla4 molecules for treating of rheumatoid arthritis
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
KR20050088136A (ko) * 2002-12-23 2005-09-01 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
SI1969007T1 (sl) 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2673725C (en) 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
BRPI0920749A8 (pt) * 2008-10-02 2017-12-12 Emergent Product Dev Seattle Proteínas de ligação de antagonista multialvo cd86
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2827492A1 (en) 2011-02-23 2012-08-30 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
EP2863936A4 (en) * 2012-05-11 2016-10-05 Medimmune Llc CTLA-4 VARIANTS
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
EP2866823A4 (en) * 2012-06-27 2016-03-02 Orban Biotech Llc CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
WO2015105609A1 (en) 2014-01-13 2015-07-16 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
BR112016028285B1 (pt) 2014-06-04 2023-02-23 Amgen Inc Método para uma colheita periódica prolongada, sistema de filtro de unidade única e método para cultivo de células que expressam proteína recombinante
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CA3036997A1 (en) 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
AU2018254547B2 (en) 2017-04-20 2024-06-13 Egenesis, Inc. Methods for generating genetically modified animals
CN111801347A (zh) 2017-10-10 2020-10-20 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
EP4021479A2 (en) 2019-08-27 2022-07-06 Tonix Pharma Limited Modified tff2 polypeptides
MY193353A (en) 2019-12-06 2022-10-06 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
KR20230026434A (ko) 2020-06-18 2023-02-24 리제너론 파아마슈티컬스, 인크. 미처리된 c-말단 리신을 정확하게 측정하기 위한 중질 펩티드 접근법
AU2021315939A1 (en) 2020-07-28 2023-02-23 Seagen Inc. Methods and systems for producing polypeptides
JP2025500887A (ja) 2021-12-16 2025-01-15 ブリストル－マイヤーズ スクイブ カンパニー ウイルス不活化用界面活性剤
EP4486778A1 (en) 2022-03-02 2025-01-08 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434131A (en) * 1991-06-27 1995-07-18 Bristol Myers Squibb Co. Chimeric CTLA4 receptor and methods for its use
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CN1244803A (zh) * 1997-01-31 2000-02-16 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变型分子及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
HU226847B1 (en) * 2000-07-03 2009-12-28 Bristol Myers Squibb Co Use of soluble ctla4 molecules for treating of rheumatoid arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434131A (en) * 1991-06-27 1995-07-18 Bristol Myers Squibb Co. Chimeric CTLA4 receptor and methods for its use
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CN1244803A (zh) * 1997-01-31 2000-02-16 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变型分子及应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432474A (zh) * 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途

Also Published As

Publication number Publication date
HK1048126A1 (en) 2003-03-21
NO2011027I1 (no) 2012-01-09
HUP0302201A2 (hu) 2003-10-28
TWI319405B (en) 2010-01-11
ATE271066T1 (de) 2004-07-15
EP1536234A3 (en) 2009-06-03
EE200200659A (et) 2004-06-15
AR031699A1 (es) 2003-10-01
EP1248802B1 (en) 2004-07-14
CA2409748A1 (en) 2001-12-06
SK15702002A3 (sk) 2004-01-08
NO20025656L (no) 2002-11-25
SK288131B6 (sk) 2013-10-02
HUP0302201A3 (en) 2010-01-28
UA87432C2 (uk) 2009-07-27
PL206267B1 (pl) 2010-07-30
LT5133B (lt) 2004-05-25
UY26723A1 (es) 2001-12-28
BE2011C041I2 (enExample) 2020-08-20
NO330797B1 (no) 2011-07-18
PE20011338A1 (es) 2002-01-13
EP1536234B1 (en) 2016-03-16
DK1248802T3 (da) 2004-11-15
IL152315A (en) 2010-04-15
MY136113A (en) 2008-08-29
RU2283847C2 (ru) 2006-09-20
NO20025656D0 (no) 2002-11-25
JP2004511213A (ja) 2004-04-15
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
BRPI0111191B8 (pt) 2021-05-25
NO2011027I2 (enExample) 2011-12-15
CA2409748C (en) 2008-09-16
KR20030009502A (ko) 2003-01-29
HK1071931A1 (en) 2005-08-05
AU6346601A (en) 2001-12-11
DE122011100063I1 (de) 2012-06-14
DE60104282D1 (de) 2004-08-19
EP1248802B9 (en) 2005-05-11
TWI314933B (en) 2009-09-21
LV12994B (en) 2003-08-20
DE60104282T2 (de) 2005-10-13
EE05557B1 (et) 2012-08-15
EE201100050A (et) 2011-10-17
EP3029062A1 (en) 2016-06-08
BR0111191A (pt) 2004-07-06
ECSP024365A (es) 2003-03-31
ZA200208944B (en) 2004-02-13
EP1536234A2 (en) 2005-06-01
PL366231A1 (en) 2005-01-24
TR200402703T4 (tr) 2004-11-22
SI1248802T1 (en) 2005-02-28
BRPI0111191B1 (pt) 2019-12-31
HU228137B1 (en) 2012-12-28
ES2225549T3 (es) 2005-03-16
TW200906857A (en) 2009-02-16
EG24459A (en) 2009-07-16
IL152315A0 (en) 2003-05-29
CZ20023892A3 (cs) 2003-09-17
KR100895134B1 (ko) 2009-05-04
GEP20053658B (en) 2005-11-10
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
CZ304451B6 (cs) 2014-05-14
EE05458B1 (et) 2011-08-15
WO2001092337A3 (en) 2002-05-10
CY1117625T1 (el) 2017-04-26
FR11C0053I1 (enExample) 2012-01-13
AU2001263466B2 (en) 2006-04-27
LT2002114A (en) 2003-12-29
ES2571852T3 (es) 2016-05-27
KR100889887B1 (ko) 2009-03-24
AU2001263466C1 (en) 2006-10-26
CY2011019I1 (el) 2016-12-14
MXPA02011534A (es) 2004-08-12
WO2001092337A2 (en) 2001-12-06
CN101255192A (zh) 2008-09-03
HUS1300012I1 (hu) 2016-08-29
FR11C0053I2 (fr) 2013-01-11
CN1441810A (zh) 2003-09-10
PT1248802E (pt) 2004-11-30
JP4328525B2 (ja) 2009-09-09
HK1048126B (en) 2005-03-04

Similar Documents

Publication Publication Date Title
CN1309735C (zh) 可溶性ctla4突变体分子及其应用
US20210115107A1 (en) Methods of treatment using ctla4 molecules
DK1935427T3 (en) APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF
HK1225393A1 (en) Soluble ctla4 mutant molecules and uses thereof
HK1071931B (en) Soluble ctla4 mutant molecules and uses thereof
NZ522031A (en) Uses of soluble CTLA4 (cytotoxic T-lymphocyte-associated protein 4) fusion molecules mutated from wild-type CTLA4 to retain the ability to bind CD80 and/or CD86

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20070411

CX01 Expiry of patent term